

HALOZYME THERAPEUTICS INC  
 Form 4  
 April 24, 2007

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Kelley Kenneth J

(Last) (First) (Middle)

C/O HALOZYME  
 THERAPEUTICS, INC., 11588  
 SORRENTO VALLEY RD., SUITE  
 17

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 HALOZYME THERAPEUTICS  
 INC [HTI]

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 04/23/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/23/2007		M <sup>(1)</sup>		25,000	A	\$ 4.1
Common Stock	04/23/2007		S <sup>(1)</sup>		1,700	D	\$ 8.75
Common Stock	04/23/2007		S <sup>(1)</sup>		1,875	D	\$ 8.76
Common Stock	04/23/2007		S <sup>(1)</sup>		300	D	\$ 8.77

## Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	2,000	D	\$ 8.78	34,125	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	2,600	D	\$ 8.79	31,525	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	2,000	D	\$ 8.8	29,525	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	1,825	D	\$ 8.81	27,700	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	300	D	\$ 8.82	27,400	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	300	D	\$ 8.83	27,100	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	1,900	D	\$ 8.84	25,200	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	2,500	D	\$ 8.85	22,700	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	1,400	D	\$ 8.86	21,300	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	600	D	\$ 8.87	20,700	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	500	D	\$ 8.88	20,200	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	300	D	\$ 8.9	19,900	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	400	D	\$ 8.91	19,500	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	400	D	\$ 8.92	19,100	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	300	D	\$ 8.93	18,800	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	200	D	\$ 8.94	18,600	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	1,500	D	\$ 8.95	17,100	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	300	D	\$ 8.96	16,800	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	200	D	\$ 8.98	16,600	D
Common Stock	04/23/2007	<u>S<sup>(1)</sup></u>	200	D	\$ 9	16,400	D
	04/23/2007	<u>S<sup>(1)</sup></u>	800	D		15,600	D



\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares purchased and sold, as applicable, pursuant to 10b5-1 Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.